Brii Biosciences Limited

OTCPK:BRIBF

Κίνα / Υγεία / Βιοτεχνολογία

Επισκόπ.

Μερίσματα

Κέρδη

Μοντέλα

Οικονομικές Καταστάσεις

Σύγκριση

Υγεία

Διαγράμματα

Ιστορικό οικ. καταστάσεων 5 ετ.

Τιμή μετοχής

0,30 USD


Key Metrics	Latest
Total Revenue	54,286 M
Adjusted EBITDA	-392,5 M
EBITDA Margin	-723,1%
Net Profit Margin	-943,9%
Total Assets	2,707 B
Total Debt	28,02 M

5Y Historical Financial Statements

Summary Financials


Summary Financials

	Fiscal Year Ending					Latest	Year-to-date Ending
(in millions)	Dec-20	Dec-21	Dec-22	Dec-23	Dec-24	12 Months	Dec-23	Dec-24

Revenue	82.22	92.54	122.28	56.32	54.29	54.29	56.32	54.29
% Growth		0.13	0.32	(0.54)	(0.04)			(0.04)

Adjusted EBITDA	(890.79)	(602.80)	(505.50)	(537.31)	(392.52)	(392.52)	(537.31)	(392.52)
% Margin	(10.83)	(6.51)	(4.13)	(9.54)	(7.23)	(7.23)	(9.54)	(7.23)

Adjusted EBIT	(896.97)	(610.48)	(513.85)	(544.30)	(399.50)	(399.50)	(544.30)	(399.50)
% Margin	(10.91)	(6.60)	(4.20)	(9.66)	(7.36)	(7.36)	(9.66)	(7.36)

Adjusted Net Income	(1,002.09)	(1,537.30)	(513.23)	(281.17)	(512.38)	(512.38)	(281.17)	(512.38)
% Margin	(12.19)	(16.61)	(4.20)	(4.99)	(9.44)	(9.44)	(4.99)	(9.44)

Adjusted Basic EPS	(5.24)	(3.50)	(0.71)	(0.39)	(0.70)	(0.70)	(0.39)	(0.70)

Υποστηρικτικοί υπολογισμοί

Income Statement

Balance Sheet

Statement of Cashflows


Income Statement
						Press Release
CNY	Fiscal Year Ending					Latest	Year-to-date Ending
(in millions)	Dec-20	Dec-21	Dec-22	Dec-23	Dec-24	Dec-24	Dec-23	Dec-24
	FY - 4	FY - 3	FY - 2	FY - 1	FY	LTM	YTD-1	YTD

Revenue	82	93	122	56	54	54	56	54
% Growth	NA	12.6%	32.1%	-53.9%	-3.6%			-3.6%

Cost of Revenue	0	0	0	0	0	0	0	0
Gross Profit	82	93	122	56	54	54	56	54
% Revenue	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

Research and Development	(876)	(495)	(441)	(403)	(250)	(250)	(403)	(250)
Selling and Marketing	0	0	(27)	(1)	0	0	(1)	0
General and Admin	(103)	(208)	(169)	(196)	(204)	(204)	(196)	(204)
Other Inc / (Exp)	(387)	(3,586)	(12)	252	(198)	(198)	252	(198)
Total Operating Exp	(1,366)	(4,289)	(648)	(348)	(651)	(651)	(348)	(651)

Operating Income	(1,284)	(4,196)	(526)	(292)	(597)	(597)	(292)	(597)
% Revenue	-1562.0%	-4534.6%	-430.3%	-518.3%	-1100.0%	-1100.0%	-518.3%	-1100.0%

Interest Expense	1	5	36	108	85	85	108	85
Pre-tax Income	(1,284)	(4,191)	(490)	(184)	(512)	(512)	(184)	(512)
Earnings of Discontinued Ops.	0	0	0	0	0	0	0	0
Provision for Taxes	0	0	0	0	0	0	0	0
Net Income to Company	(1,284)	(4,191)	(490)	(184)	(512)	(512)	(184)	(512)
% Margin	-1561.1%	-4528.8%	-400.5%	-327.3%	-943.9%	-943.9%	-327.3%	-943.9%

Minority Interest in Earnings	94	27	5	10	4	4	10	4
Net Income to Stockholders	(1,190)	(4,164)	(484)	(175)	(508)	(508)	(175)	(508)

Preferred Dividends	0	0	0	0	0	0	0	0
Other Adj.	0	0	0	0	0	0	0	0

Net Income to Common	(1,190)	(4,164)	(484)	(175)	(508)	(508)	(175)	(508)
% Margin	-1446.9%	-4499.4%	-396.1%	-310.4%	-936.1%	-936.1%	-310.4%	-936.1%

As Reported
Basic EPS (Continuing Ops)	(6.22)	(9.48)	(0.67)	(0.24)	(0.70)	(0.70)	(0.24)	(0.70)
Diluted EPS (Continuing Ops)	(6.22)	(9.48)	(0.67)	(0.24)	(0.70)	(0.70)	(0.24)	(0.70)

WA Basic Shares Out.	191.25	439.05	723.48	728.10	730.25	730.25	728.10	730.25
WA Diluted Shares Out.	191.25	439.05	723.48	728.10	730.25	730.25	728.10	730.25

EBITDA, EBIT Reconciliation
EBT, Incl. Unusual Items	(1,284)	(4,191)	(490)	(184)	(512)	(512)	(184)	(512)
Addback: Net Interest Expense	(1)	(5)	(36)	(108)	(85)	(85)	(108)	(85)
Addback: Other Non Operating Expenses, Total	7	(0)	44	(122)	198	198	(122)	198
Addback: Depreciation & Amortization	6	8	8	7	7	7	7	7
Addback: Restructuring Charges	0	0	0	0	0	0	0	0
Addback: Merger / Acquisition Expenses	0	0	0	0	0	0	0	0
Addback: Goodwill Impairment	0	0	0	0	0	0	0	0
Addback: Gain (Loss) On Sale Of Invest.	15	(45)	(32)	(136)	0	0	(136)	0
Addback: Gain (Loss) On Sale Of Assets	0	0	0	0	0	0	0	0
Addback: Asset Writedown	0	0	0	5	0	0	5	0
Addback: In Process R&D Expenses	0	0	0	0	0	0	0	0
Addback: Insurance Settlements	0	0	0	0	0	0	0	0
Addback: Legal Settlements	0	0	0	0	0	0	0	0
Addback: Other Unusual Items	365	3,631	0	0	0	0	0	0
Adjusted EBITDA	(891)	(603)	(505)	(537)	(393)	(393)	(537)	(393)
% Margin	-1083.4%	-651.4%	-413.4%	-954.0%	-723.1%	-723.1%	-954.0%	-723.1%

Adjusted EBIT	(897)	(610)	(514)	(544)	(400)	(400)	(544)	(400)
% Margin	-1091.0%	-659.7%	-420.2%	-966.4%	-735.9%	-735.9%	-966.4%	-735.9%

Adjusted Net Income Reconciliation
Net Income to Company	(1,284)	(4,191)	(490)	(184)	(512)	(512)	(184)	(512)
Addback: Unusual Items	380	3,586	(32)	(131)	0	0	(131)	0
Less: Tax Benefit of Unusual Items (26%)	(99)	(932)	8	34	0	0	34	0
Adjusted Net Income	(1,002)	(1,537)	(513)	(281)	(512)	(512)	(281)	(512)
% Margin	-1218.8%	-1661.2%	-419.7%	-499.2%	-943.9%	-943.9%	-499.2%	-943.9%

Με επιφύλαξη παντός δικαιώματος. Όροι Χρήσης

Σφάλμα φόρτωσης

Brii Biosciences Limited

OTCPK:BRIBF

Κίνα / Υγεία / Βιοτεχνολογία

Ιστορικό οικ. καταστάσεων 5 ετ.